Table S1. Adverse events.

Variable	6M	12M	24M	36M	48M
Procedures, n	431	439	338	245	203
VA Loss ≥10 Letters 0-6M (%)	174 (40%)	140 (32%)	106 (31%)	75 (31%)	43 (21%)
VA Loss ≥10 Letters 6-12M (%)		54 (12%)	39 (12%)	23 (9.4%)	15 (7.4%)
VA Loss ≥10 Letters 12-24M (%)			41 (12%)	25 (10%)	16 (7.9%)
Bleb Needling 0-6M (%)	93 (22%)	81 (18%)	65 (19%)	42 (17%)	29 (14%)
Bleb Needling 6-12M (%)		21 (4.8%)	17 (5%)	14 (5.7%)	7 (3.4%)
Bleb Needling 12-24M (%)			15 (4.4%)	12 (4.9%)	7 (3.4%)
Bleb Needling 24-36M (%)				2 (0.82%)	2 (0.99%)
Bleb Needling 36-48M (%)					2 (0.99%)
Hypotony 0-6M (%)	133 (31%)	114 (26%)	92 (27%)	58 (24%)	37 (18%)
Hypotony 6-12M (%)		4 (0.91%)	3 (0.89%)	3 (1.2%)	0 (0%)
Hypotony 12-24M (%)			5 (1.5%)	4 (1.6%)	1 (0.49%)
Hypotony 24-36M (%)				1 (0.41%)	1 (0.49%)
Hypotony 36-48M (%)					0 (0%)
Hypotony 0-6M+VA Loss ≥10 Letters 0-6M (%)	74 (17%)	64 (15%)	50 (15%)	30 (12%)	15 (7.4%)
Hypotony 6-12M+VA Loss ≥10 Letters 6-12M (%)		2 (0.46%)	2 (0.59%)	2 (0.82%)	0 (0%)

Hypotony 12-24M+VA Loss ≥10 Letters 12-24M (%)			4 (1.2%)	4 (1.6%)	1 (0.49%)
Hypotony 24-36M+VA Loss ≥10 Letters 24-36M (%)				1 (0.41%)	1 (0.49%)
Hypotony 36-48M+VA Loss ≥10 Letters 36-48M (%)					0 (0%)
Hyphaema 0-6M (%)	20 (4.6%)	15 (3.4%)	12 (3.6%)	10 (4.1%)	6 (3%)
Hyphaema 6-48M (%)		0 (0%)	0 (0%)	0 (0%)	0 (0%)
Glaucoma Device Malposition 0-6M (%)	10 (2.3%)	8 (1.8%)	7 (2.1%)	3 (1.2%)	4 (2%)
Glaucoma Device Malposition 6-12M (%)		1 (0.23%)	1 (0.3%)	1 (0.41%)	1 (0.49%)
Glaucoma Device Malposition 12-48M (%)			0 (0%)	0 (0%)	0 (0%)
Choroidal Effusions 0-6M (%)	21 (4.9%)	16 (3.6%)	13 (3.8%)	4 (1.6%)	4 (2%)
Choroidal Effusions 6-12M (%)		0 (0%)	0 (0%)	0 (0%)	0 (0%)
Choroidal Effusions 12-24M (%)			1 (0.3%)	0 (0%)	0 (0%)
Choroidal Effusions 24-48M (%)				0 (0%)	0 (0%)
Corneal Decompensation 0-6M (%)	4 (0.93%)	3 (0.68%)	3 (0.89%)	3 (1.2%)	3 (1.5%)
Hyphaema 0-6M+VA Loss ≥10 Letters 0-6M (%)	13 (3%)	9 (2.1%)	8 (2.4%)	6 (2.4%)	3 (1.5%)
Hypotony Maculopathy 0-6M (%)	7 (1.6%)	6 (1.4%)	7 (2.1%)	4 (1.6%)	3 (1.5%)
Shallow AC 0-6M (%)	9 (2.1%)	8 (1.8%)	5 (1.5%)	4 (1.6%)	2 (0.99%)
Glaucoma Device Exposure 0-6M (%)	6 (1.4%)	4 (0.91%)	4 (1.2%)	2 (0.82%)	2 (0.99%)
Glaucoma Device Exposure 6-2M (%)		2 (0.46%)	1 (0.3%)	0 (0%)	0 (0%)
Glaucoma Device Exposure 12-24M (%)			1 (0.3%)	1 (0.41%)	0 (0%)

Glaucoma Device Exposure 24-48M (%)				0 (0%)	0 (0%)
Bleb Dysaesthesia 0-6M (%)	2 (0.46%)	2 (0.46%)	2 (0.59%)	0 (0%)	0 (0%)
Bleb Dysaesthesia 6-12M (%)		1 (0.23%)	0 (0%)	0 (0%)	0 (0%)
Bleb Dysaesthesia 12-24M (%)			2 (0.59%)	1 (0.41%)	1 (0.49%)
Stent Obstruction 0-6M (%)	9 (2.1%)	8 (1.8%)	5 (1.5%)	3 (1.2%)	0 (0%)
Stent Obstruction 6-24M (%)		0 (0%)	0 (0%)	0 (0%)	0 (0%)
Corneal Epithelial Toxicity From Antimetabolite 0-6M (%)	2 (0.46%)	1 (0.23%)	0 (0%)	0 (0%)	0 (0%)
Infectious Endophthalmitis 0-6M (%)	1 (0.23%)	1 (0.23%)	0 (0%)	0 (0%)	0 (0%)
Conjunctival Leak 0-6M (%)	2 (0.46%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

M = month.

Data are presented as n (%)

[a] Eligible procedures were ones that had at least one visit 6 months (150–335 days) after the procedures themselves were performed. The same applied to the 12M, 24M, 36M. and 48M.

None of the following adverse events were observed: binocular double vision, blebitis, blebitis with endophthalmitis, cyclodialysis cleft, Intraocular lens dislocation, malignant glaucoma, peripheral anterior synechiae associated with stent, postsurgical scleritis, ptosis, reformation of anterior chamber, or suprachoroidal haemorrhage.

Table S2. Secondary glaucoma procedures after Xen stand-alone or Xen+Cataract surgery.

	6M	12M	24M	36M	48M
Procedures, n	431 (100%)	439 (100%)	338 (100%)	245 (100%)	203 (100%)
Any of the below Procedures	43 (10%)	57 (13%)	62 (18%)	45 (18%)	34 (17%)
Trabeculectomy 0-6M	6 (1.4%)	5 (1.1%)	4 (1.2%)	1 (0.41%)	2 (0.99%)
Trabeculectomy 6-12M		6 (1.4%)	7 (2.1%)	2 (0.82%)	2 (0.99%)
Trabeculectomy 12-24M			6 (1.8%)	4 (1.6%)	3 (1.5%)
Trabeculectomy 24-36M				8 (3.3%)	5 (2.5%)
Trabeculectomy 36-48M					5 (2.5%)
Revision Of Glaucoma Device 0-6M	19 (4.4%)	16 (3.6%)	12 (3.6%)	10 (4.1%)	7 (3.4%)
Revision Of Glaucoma Device 6-12M		7 (1.6%)	6 (1.8%)	4 (1.6%)	2 (0.99%)
Revision Of Glaucoma Device 12-24M			2 (0.59%)	2 (0.82%)	1 (0.49%)
Revision Of Glaucoma Device 24-48M				0 (0%)	0 (0%)
Xen Implant 0-6M	3 (0.7%)	3 (0.68%)	3 (0.89%)	1 (0.41%)	1 (0.49%)
Xen Implant 6-48M		0 (0%)	0 (0%)	0 (0%)	0 (0%)
Revision Of Glaucoma Device Cataract 0-12M	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Revision Of Glaucoma Device Cataract 12-24M			2 (0.59%)	1 (0.41%)	1 (0.49%)
Revision Of Glaucoma Device Cataract 24-48M				0 (0%)	0 (0%)
Revision Trabeculectomy_0-6M	3 (0.7%)	0 (0%)	1 (0.3%)	0 (0%)	0 (0%)

Revision Trabeculectomy 6-12M		2 (0.46%)	1 (0.3%)	0 (0%)	0 (0%)
Revision Trabeculectomy 12-24M			1 (0.3%)	0 (0%)	0 (0%)
Revision Trabeculectomy 24-48M				0 (0%)	0 (0%)
Revision Trabeculectomy Cataract 0-6M	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Revision Trabeculectomy Cataract 6-12M		1 (0.23%)	1 (0.3%)	0 (0%)	0 (0%)
Revision Trabeculectomy Cataract 12-48M			0 (0%)	0 (0%)	0 (0%)

[a] Eligible procedures were ones that had at least one visit 6 months (150–335 days) after the procedures themselves were performed. The same applied to the 12M, 24M 36M and 48M.